financetom
Business
financetom
/
Business
/
DuPont's Breakup Plan Holds Logic Amid Disadvantages, BofA Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DuPont's Breakup Plan Holds Logic Amid Disadvantages, BofA Says
May 28, 2024 11:17 AM

01:47 PM EDT, 05/28/2024 (MT Newswires) -- DuPont de Nemours' ( DD ) plan to split up holds clear logic in capturing higher valuations for its Water and Electronics businesses while also showing some disadvantages from smaller market values, BofA Securities said in a note.

Last week, DuPont ( DD ) said it would split into three publicly traded companies, proposing separations of its Electronics and Water businesses in a tax-free manner to shareholders with New DuPont continuing as a diversified industrial company.

Investor interest has been moderate due to the uncertain magnitude of per- and polyfluoroalkyl substances liabilities and the diversity of businesses constraining valuation to well below specialty chemical peers, the report said.

"If a deal were to happen on the announced terms, the breakup would create pure-plays in two end markets with significant long-term growth potential, driven by water shortages and societal electrification, and which we believe could trade at higher

multiples," BofA said.

The report also pointed to challenges to sum-of-the-parts valuation, including a greater PFAS liability risk to the smaller entities, and possible lower multiple for industrial and water businesses against peers.

"While the company's plan to split into 3 companies could create potential upside in our view it will still create 3 smaller

companies that still have PFAS liabilities," the report said.

BofA reiterated its underperform rating on DuPont ( DD ) while raising its price objective to $80 from $74.

Price: 82.19, Change: +1.07, Percent Change: +1.32

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Zentek Says Unit Achieves 'Ultra-High Purity' on Graphite Sample
Zentek Says Unit Achieves 'Ultra-High Purity' on Graphite Sample
Jul 17, 2024
07:57 AM EDT, 07/17/2024 (MT Newswires) -- Zentek ( ZTEK ) said Wednesday its subsidiary, Albany Graphite, has achieved a five nines purity of 99.99915% for a graphite sample from the Albany graphite deposit. Zentek ( ZTEK ) said the material will immediately be tested for suitability for both the lithium-ion battery and nuclear markets. ...
Citizens Financial's profit beats estimates on strong capital markets
Citizens Financial's profit beats estimates on strong capital markets
Jul 17, 2024
(Reuters) - Citizens Financial beat expectations for second-quarter profit on Wednesday, as strong capital markets softened the hit from weaker lending. A resilient U.S. economy has encouraged corporate executives to raise capital via bond sales, boosting the fees at investment banks that underwrite such deals. Capital markets fees surged 63%, driven by bond underwriting and loan syndication, Citizens said. Its...
Mercedes-Benz unit partners with Starbucks for fast-charging stations in US
Mercedes-Benz unit partners with Starbucks for fast-charging stations in US
Jul 17, 2024
July 17 (Reuters) - A Mercedes-Benz unit said on Wednesday it had partnered with Starbucks ( SBUX ) to deploy its fast-charging stations at more than 100 locations across the United States. The first phase of the program will have 400 kW EV chargers at Starbucks ( SBUX ) stores along Interstate 5, a west coast travel corridor spanning from...
Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason
Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason
Jul 17, 2024
JERUSALEM, July 17 (Reuters) - Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round. Nvidia ( NVDA ), Pfizer ( PFE ), Thermo Fisher and venture capital investor OurCrowd participated in the round, CytoReason said. The company said it aims to expand the application of its models...
Copyright 2023-2026 - www.financetom.com All Rights Reserved